Navidea Biopharmaceuticals (NAVB) Misses Q2 EPS by 2c

August 7, 2013 7:50 AM

Navidea Biopharmaceuticals (NYSE: NAVB) reported Q2 EPS of ($0.09), $0.02 worse than the analyst estimate of ($0.07). Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found